RASAGILIN in English translation

• rasagiline

Examples of using Rasagilin in Danish and their translations into English

Det er vist, at rasagilin er en potent,
Rasagiline was shown to be a potent,

I de dobbeltblinde, placebokontrollerede undersøgelser blev 529 patienter behandlet med rasagilin 1 mg dagligt i 212 patientår, og 539 patienter fik placebo i 213 patientår.
In the double blind placebo controlled studies 529 patients were treated with rasagiline 1 mg/ day for 212 patient years and 539 patients received placebo for 213 patient years.

Rasagilin var ikke carcinogen i rotter ved systemisk koncentration,
Rasagiline was not carcinogenic in rats at systemic exposure,

Andre bivirkninger af betydning, som blev observeret i kliniske undersøgelser med rasagilin(anden dosis eller i undersøgelser uden placebokontrol),
Other important adverse events that were reported in clinical studies with rasagiline(other dose

I undersøgelse II blev patienterne randomiseret til behandling i 18 uger med enten placebo(229 patienter) eller rasagilin 1 mg dagligt(231 patienter) eller til behandling med 200 mg entakapon,
In study II patients were randomly assigned to receive placebo(229 patients), or rasagiline 1 mg/ day(231 patients)

In vitro undersøgelser viste, at rasagilin ikke hæmmede cytochrom P450 isoenzymer, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 og CYP4A i en koncentration på 1μg/ ml svarende til en koncentration, som er 160 gange højere end det gennemsnitlige Cmax ∼ 5, 9- 8, 5 ng/ ml hos patienter med Parkinsons sygdom efter indtagelse af 1 mg rasaglin som multipel dosis.
In vitro studies showed that rasagiline at a concentration of 1 µg/ ml(equivalent to a level that is 160 times the average Cmax~ 5.9-8.5 ng/ ml in Parkinson' s disease patients after 1 mg rasagiline multiple dosing), did not inhibit cytochrome P450 isoenzymes, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP4A.

I undersøgelse III blev patienterne randomiseret til behandling i 26 uger med enten placebo(159 patienter), rasagilin 0, 5 mg dagligt(164 patienter) eller rasagilin 1 mg dagligt 149 patienter.
In study III patients were randomly assigned to receive placebo(159 patients), rasagiline 0.5 mg/ day(164 patients), or rasagiline 1 mg/ day(149 patients), and were treated for 26 weeks.

I undersøgelse I blev 404 patienter randomiseret til behandling med enten placebo(138 patienter), rasagilin 1 mg dagligt(134 patienter) eller rasagilin 2 mg dagligt(132 patienter)
In study I, 404 patients were randomly assigned to receive placebo(138 patients), rasagiline 1 mg/ day(134 patients)

der ikke sås tyramin/ rasagilin interaktion i kliniske undersøgelser gennemført uden restriktioner i tyraminindtagelse,
the fact that there were no reports of tyramine/ rasagiline interaction in clinical studies conducted without tyramine restriction,

Hvad er bivirkningerne af Azilect(Rasagilin Mesylat)?
What are the side effects of Azilect(Rasagiline Mesylate)?

Hvordan skal jeg bruge Azilect(rasagilin mesylat)?
How should I use Azilect(Rasagiline Mesylate)?

Hvad er bivirkninger af Azilect(rasagilin mesylat)?
What are the side effects of Azilect(Rasagiline Mesylate)?

Azilect(Rasagilin Mesylat) bruges til behandling af Parkinsons sygdom.
Azilect(Rasagiline Mesylate) is used to treat the symptoms of Parkinson's disease.

Azilect(rasagilin mesylat) anvendes til behandling af symptomerne på Parkinsons sygdom.
Azilect(Rasagiline Mesylate) is used to treat the symptoms of Parkinson's disease.

Det aktive stof i AZILECT, rasagilin, er en monoaminoxidase- B(MAO)- hæmmer.
The active substance in AZILECT, rasagiline, is a monoamine oxidase-B inhibitor.

Rasagilin er kontraindiceret hos patienter med alvorligt nedsat leverfunktion.
Rasagiline is contraindicated in patients with severe hepatic insufficiency.

Data fra undersøgelser indikerede, at rasagilin hæmmer prolaktinsekretionen
Experimental data indicated that rasagiline inhibits prolactin secretion

Rasagilin viste statistisk signifikante fordele sammenlignet med placebo.
Rasagiline produced statistically significant benefit compared to placebo.

Metaboliseringen af rasagilin sker via to hovedmetaboliseringsveje.
The metabolism of rasagiline proceeds through two main pathways.

AZILECT er et lægemiddel, der indeholder det aktive stof rasagilin.
AZILECT is a medicine containing the active ingredient rasagiline.